ArticleCancer immunology, immunotherapy : CII2026
Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High frequency and activity of tumor-infiltrating natural killer (NK) cell is associated with improved prognosis in several solid cancers including non-small cell lung cancer. However, multiple factors can suppress NK cell activity within the tumor microenvironment, resulting in impaired killing of tumor cells. For NK cells to engage and kill target cells, stabilization of lipid rafts is essential. Sphingomyelin is involved in lipid raft formation and is catabolized by sphingomyelinases. While inhibition of sphingomyelinases enhances NK cell-mediated killing of tumor cells, it is unknown how sphingomyelinases impact on the ability of NK cells to infiltrate solid tumors. Here we demonstrate that inhibition of sphingomyelinases results in increased activation and ability of NK cells to infiltrate lung adenocarcinoma. Overall, our findings support the use of sphingomyelinase inhibitors as enhancers of NK cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.